6c3fd2dd__Trials_Monthly___October_2013__Description
[NCI Designation] NCT01718353 [Disease Site] Prostate Cancer [Description] 
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Seattle Cancer Care Alliance | Clinical Trials Monthly - October 2013
Description